Researchers at ETH Zurich combined two CRISPR-Cas methods to decipher how mutations in a cell’s genome affect its function.

The prime editor is a fusion protein consisting of a catalytically impaired Cas9 nickase (Cas9n) and an engineered reverse transcriptase (RT). The Cas9n is guided by a prime editing guide RNA (pegRNA) ...

Prime editing, a versatile form of gene editing that can correct most known disease-causing genetic mutations, now has a new vehicle to deliver its machinery into cells in living animals.

In recent years, scientists have created a range of new methods based on CRISPR-Cas technology for precisely editing the ...

For several years, a rivalry has been brewing between two high-profile gene-editing companies. On one hand is Prime Medicine, built on prime editing, a technology out of David’s Liu lab at the ...

Prime Medicine has been given the go-ahead by the FDA for the first human trial of its prime editing technology, which promises to deliver one-shot therapies for a range of severe genetic diseases.

to initiate trials of the first-ever prime editing drug. The FDA cleared Prime Medicine’s investigational new drug (IND) application for PM359 for the treatment of chronic granulomatous disease ...

Arthur He CFA has given his Buy rating due to a combination of factors that demonstrate Prime Medicine’s promising advancements in gene editing technologies. The company showcased significant ...

The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic ...

Gene-editing biotech Prime Medicine has priced a follow-on public offering, hoping to raise $140 million to advance its pipeline of one-shot therapies for severe genetic disorders. The Cambridge ...

today announced the Company will highlight advances from across its Prime Editing pipeline and platform at the upcoming European Society of Gene and Cell Therapy (ESGCT) 31 st Annual Congress ...